prednisone + vincristine + methotrexate + doxorubicin + cyclophosphamide + etoposide

This is a combination regimen of six anticancer drugs—prednisone (a steroid), vincristine (a vinca alkaloid), methotrexate (an antifolate), doxorubicin (an anthracycline), cyclophosphamide (an alkylating agent), and etoposide (a topoisomerase II inhibitor). No published studies or official guidelines refer to this exact six-drug combination as a standard regimen. Each of these drugs is routinely used in various cancer treatment protocols (e.g., cyclophosphamide, doxorubicin, and vincristine are components of the CHOP regimen; etoposide is commonly added in many lymphoma and sarcoma regimens), but the precise combination listed appears to be either investigational, institution-specific, or a researcher-designed cocktail, and does not have a recognized consensus indication or regimen name in the literature. The closest published combinations include three to five of these drugs, but not all six together in a single, standardized regimen.